



OFFICE OF THE DEPARTMENT OF DEFENSE COORDINATOR
FOR DRUG ENFORCEMENT POLICY AND SUPPORT

1510 DEFENSE PENTAGON
WASHINGTON DC 20301-1510

24 MAR 1997



MEMORANDUM FOR ASSISTANT SECRETARY OF THE ARMY (MANPOWER AND
RESERVE AFFAIRS)
ASSISTANT SECRETARY OF THE NAVY (MANPOWER AND
RESERVE AFFAIRS)
DEPUTY ASSISTANT SECRETARY OF THE AIR FORCE (FORCE
MANAGEMENT AND PERSONNEL)

SUBJECT: Amphetamines Screening in the Demand Reduction Drug Testing Program

The current immunoassay screening procedure for amphetamine employed in the Demand Reduction Drug Testing program is sensitive to the presence of various cold medication products (ephedrine, pseudoephedrine, and phenylpropanolamine) and to the presence of various diet medications (fenfluramine). To eliminate such interference, the use of adjunct testing is permitted following the initial amphetamines screening procedure on the Olympus AU800.

Periodate may be employed to eliminate interference associated with cold medications; however, periodate will not remove interference associated with weight loss medications. To eliminate the latter interference, the use of the Behring Diagnostics Monoclonal Amphetamine/Methamphetamine Emit II reagents also may be employed as a adjunct to the initial screen.

In the use of the adjunct procedures, the forensic accuracy and documentation required in testing shall be maintained. Additional guidance is provided:

The initial screen for amphetamines on the Olympus AU800 will be conducted using the Roche On-Line reagents as licensed for use. Specimens which are presumptive positive as a result of the initial screen may be subject to adjunct amphetamine testing. The adjunct testing may be conducted using either the initial screened aliquot sample tested on the Olympus AU800 or using freshly poured aliquot from the original specimen container. Chain of custody requirements and documentation must be considered in the course of the adjunct testing. Additional testing requirements imposed by the Services or the requirement for rescreen analyses employing water or negative blanks between samples are not abrogated.

Modifications to the Laboratory Operating Procedures (LOP) manual and Standard Operating Procedures (SOP) manual are required prior to implementation of the adjunct testing procedures. Additional information regarding adjunct screening analyses for amphetamines may be obtained by contacting Captain John Jemionek, MSC, USN, Science and Testing Programs Officer at (703) 693-1917 or DSN 223-1917.


Robert J. Newberry

Principal Director for
Drug Enforcement Policy and Support

CF:
Demand Reduction Drug Laboratories

